To include your compound in the COVID-19 Resource Center, submit it here.

Lexicon's sotagliflozin meets secondary endpoints in Phase III for Type I diabetes

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) reported additional data from the 24-week Phase III inTandem2 trial in 782 Type I diabetics inadequately controlled with insulin showing that once-daily 200 and 400 mg doses of oral sotagliflozin (SAR439954)

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE